At a glance
| Approved product | Firazyr and generics |
|---|---|
| Main target | Bradykinin B2 receptor |
| Molecular size | Ten amino acids |
| U.S. indication | Acute HAE attacks in adults |
| Common adverse effect | Injection-site reactions |
Overview
Icatibant is a ten-amino-acid analog designed to prevent bradykinin from producing its vascular effects. In hereditary angioedema, excessive bradykinin activity can cause painful or dangerous swelling. Firazyr and generic icatibant products address acute attacks rather than correcting the inherited cause. The disease context matters because swelling can arise through different biological pathways. A medicine effective in bradykinin-mediated HAE cannot automatically be assumed effective in histamine-mediated allergy or every case of drug-associated angioedema. Its skin-category placement reflects visible swelling, while abdominal and airway manifestations are also important parts of the clinical condition.
How it works
Icatibant competitively antagonizes the bradykinin B2 receptor. Blocking that receptor reduces bradykinin-mediated increases in vascular permeability and associated symptoms. This mechanism acts downstream from kallikrein inhibition and is distinct from replacing C1 inhibitor. Receptor selectivity explains the treatment rationale, but clinical trials and product labeling are still needed to define the populations and attacks for which benefit is established.
The FAST-3 controlled trial
For cutaneous or abdominal attacks, FAST-3 randomized 43 participants to icatibant and 45 to placebo. Median time to at least a 50% symptom-severity reduction was approximately two hours with icatibant versus nearly twenty hours with placebo. The study supports faster relief in the investigated HAE setting; its findings should not be generalized to unrelated swelling mechanisms.
Supporting sources [2]
Local reactions and clinical context
Injection-site reactions are common. The label allows trained patients to self-administer the approved product, but that does not remove the need for an established clinical plan. Laryngeal attacks require immediate medical attention even after treatment because airway compromise can remain dangerous.
Supporting sources [1]
Specific approval, separate research questions
The U.S. label covers adults with acute HAE attacks. Pediatric authorizations and other uses must be checked by jurisdiction. Research in other bradykinin-related conditions is a distinct evidence question; biological plausibility alone does not expand the approved indication. Approval of a finished prescription product also does not validate an unregulated research preparation.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic decapeptide bradykinin-B2-receptor antagonist.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Firazyr (icatibant) prescribing information ↗Regulatory source · Checked 2026-10-27
- FAST-3: randomized placebo-controlled icatibant trial in acute HAE ↗Clinical trial source · Checked 2026-10-27